Form 4: Lineage Cell Therapeutics CEO's RSU Vesting

Lineage Cell Therapeutics CEO Brian M. Culley reported the vesting of 8,925 restricted stock units and the withholding of 334 shares for tax purposes.

Summary

• Brian M. Culley, President and CEO of Lineage Cell Therapeutics, Inc. (LCTX), reported changes in beneficial ownership.
• On December 19, 2025, Mr. Culley acquired 8,925 common shares due to the vesting of restricted stock units (RSUs).
• These RSUs were granted on February 11, 2022, and their vesting was contingent on achieving certain performance conditions.
• The RSUs are settled on a one-for-one basis in common shares.
• Concurrently, 334 common shares were disposed of by the issuer to satisfy statutory tax withholding requirements related to the RSU vesting.
• The shares withheld for tax purposes were valued at $1.68 per share.
• Following these transactions, Mr. Culley directly beneficially owns 222,135 common shares.
• The reported beneficial ownership does not include unvested RSUs or common shares acquirable upon the exercise of outstanding stock options.

Sentiment

Score: 7

Explanation: The filing reports a routine executive compensation event (RSU vesting) which indicates performance conditions were met. While positive for the executive and a sign of internal goal achievement, it is a standard, non-discretionary transaction with minimal direct market impact.

Positives

• The vesting of 8,925 restricted stock units indicates that certain performance conditions set by the company for its CEO, Brian M. Culley, were met.
• This transaction is a routine part of executive compensation, aligning management's interests with shareholder value through equity ownership.

Negatives

• 334 shares were withheld by the issuer to cover statutory tax obligations, which is a standard procedure for RSU vesting and not a discretionary sale by the executive.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This Form 4 filing is a routine disclosure of an insider transaction related to executive compensation, common across all publicly traded companies. It reflects the standard process of restricted stock unit vesting and associated tax withholding for a company executive.

Stakeholder Impact

• Shareholders: The vesting of RSUs for the CEO indicates that performance targets, which align with shareholder interests, have been met. This is a positive signal regarding executive performance and retention.
• Employees: This transaction is part of a standard executive compensation package, which can serve as a benchmark or motivator for other employees with similar equity awards.

Key Dates

Recommendation

This Form 4 filing details a routine vesting of restricted stock units and the associated tax withholding for the CEO. Such transactions are standard components of executive compensation and do not typically signal a change in the company's fundamental value, operational performance, or strategic outlook. Therefore, it does not provide new information that would warrant a change from a 'hold' recommendation.

Keywords

LCTX, Lineage Cell Therapeutics, Brian M. Culley, Form 4, Restricted Stock Units, RSU vesting, Insider Transaction, Executive Compensation, Stock Ownership